English
English Indonesia Türkçe Deutsch Español Português Pусский Français Italiano Nederlands Polski العربية ไทย Tiếng Việt 繁體中文 简体中文 日本語 한국어

#talapro2 search results

OncBrothers's profile picture. Practice changing discussions by community oncologists-Rohit Gosain @RoswellPark & Rahul Gosain @WilmotCancer. OwnViews/NoMedAdvice.COI https://t.co/cJOjp0RvQE
Oncology Brothers
@OncBrothers
Feb 16

#GU25 highlights #CommunityOnc: 1. Radical ✂️ vs. XRT high risk PCa 2. #TALAPRO2: PARPi in M1 CRPC 3. #EnzaP: ARPi + LuPSMA in M1 CRPC 4. #NIAGARA update: Resectable MIBC 5. #EV302 update: Metastatic #BladderCancer 6. #CM9ER update: 1L mRCC #OncTwitter #gism @ASCO 1/7

OncBrothers's tweet image. #GU25 highlights #CommunityOnc: 1. Radical ✂️ vs. XRT high risk PCa 2. #TALAPRO2: PARPi in M1 CRPC 3. #EnzaP: ARPi + LuPSMA in M1 CRPC 4. #NIAGARA update: Resectable MIBC 5. #EV302 update: Metastatic #BladderCancer 6. #CM9ER update: 1L mRCC #OncTwitter #gism @ASCO 1/7
6
85
220
143
33K
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
Nov 10

Overall survival results from the #TALAPRO2 trial in #mCRPC patients. @neerajaiims @huntsmancancer joins Oliver Sartor, MD @EJHospital to discuss the OS results from the TALAPRO-2 trial, which led to approval of talazoparib + enzalutamide for metastatic castration-resistant…

0
3
5
0
794
drenriquegrande's profile picture. Medical Oncology Department Director at Quironsalud Madrid. Opinions are my own. https://t.co/DrJu4J331O
Enrique Grande
@drenriquegrande
Feb 16, 2023

Huge congrats to @neerajaiims Wonderful talk and results with direct implications for the clinic. #Talapro2 at @ASCO #GU23 @OncoAlert

drenriquegrande's tweet image. Huge congrats to @neerajaiims Wonderful talk and results with direct implications for the clinic. #Talapro2 at @ASCO #GU23 @OncoAlert
drenriquegrande's tweet image. Huge congrats to @neerajaiims Wonderful talk and results with direct implications for the clinic. #Talapro2 at @ASCO #GU23 @OncoAlert
1
15
71
2
10K
TiansterZhang's profile picture. I treat & research GU cancers @UTSW Dallas. Columbia/Harvard Med/Duke alum; Mom & wife Tweets=my opinions ASCO: https://t.co/Whk29PBrMM
Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)
 @TiansterZhang
Feb 16, 2023

Always dynamic, @neerajaiims takes us thru #TALAPRO2 for mCRPC — talazoparib w enzalutamide prolonged disease progression vs enza w placebo. Effect more in HRR+ pts but ➕in all pts. Some cytopenias which we expect on PARP inhibitors. Great work from @PfizerOncMed & study teams!

TiansterZhang's tweet image. Always dynamic, @neerajaiims takes us thru #TALAPRO2 for mCRPC — talazoparib w enzalutamide prolonged disease progression vs enza w placebo. Effect more in HRR+ pts but ➕in all pts. Some cytopenias which we expect on PARP inhibitors. Great work from @PfizerOncMed & study teams!
TiansterZhang's tweet image. Always dynamic, @neerajaiims takes us thru #TALAPRO2 for mCRPC — talazoparib w enzalutamide prolonged disease progression vs enza w placebo. Effect more in HRR+ pts but ➕in all pts. Some cytopenias which we expect on PARP inhibitors. Great work from @PfizerOncMed & study teams!
TiansterZhang's tweet image. Always dynamic, @neerajaiims takes us thru #TALAPRO2 for mCRPC — talazoparib w enzalutamide prolonged disease progression vs enza w placebo. Effect more in HRR+ pts but ➕in all pts. Some cytopenias which we expect on PARP inhibitors. Great work from @PfizerOncMed & study teams!
TiansterZhang's tweet image. Always dynamic, @neerajaiims takes us thru #TALAPRO2 for mCRPC — talazoparib w enzalutamide prolonged disease progression vs enza w placebo. Effect more in HRR+ pts but ➕in all pts. Some cytopenias which we expect on PARP inhibitors. Great work from @PfizerOncMed & study teams!
0
12
36
0
6K
Dr_RaviMadan's profile picture. Clinical researcher focused on #ProstateCancer, early recurrence (#BCR) & #immunotherapy. Views are my own & do not represent the National Cancer Institute
Ravi A Madan M.D.
 @Dr_RaviMadan
Feb 16, 2023

#Talapro2 #ProstateCancer @asco #GU23 @neerajaiims @Huntsman_GU presents the data of first line #mCRPC of #parp inhibitor & enzalutamide Clear benefit in progression free survival w/expected added toxicity Surprising that with a nearly 50% event rate, OS is not impacted yet🧐

Dr_RaviMadan's tweet image. #Talapro2 #ProstateCancer @asco #GU23 @neerajaiims @Huntsman_GU presents the data of first line #mCRPC of #parp inhibitor & enzalutamide Clear benefit in progression free survival w/expected added toxicity Surprising that with a nearly 50% event rate, OS is not impacted yet🧐
Dr_RaviMadan's tweet image. #Talapro2 #ProstateCancer @asco #GU23 @neerajaiims @Huntsman_GU presents the data of first line #mCRPC of #parp inhibitor & enzalutamide Clear benefit in progression free survival w/expected added toxicity Surprising that with a nearly 50% event rate, OS is not impacted yet🧐
Dr_RaviMadan's tweet image. #Talapro2 #ProstateCancer @asco #GU23 @neerajaiims @Huntsman_GU presents the data of first line #mCRPC of #parp inhibitor & enzalutamide Clear benefit in progression free survival w/expected added toxicity Surprising that with a nearly 50% event rate, OS is not impacted yet🧐
Dr_RaviMadan's tweet image. #Talapro2 #ProstateCancer @asco #GU23 @neerajaiims @Huntsman_GU presents the data of first line #mCRPC of #parp inhibitor & enzalutamide Clear benefit in progression free survival w/expected added toxicity Surprising that with a nearly 50% event rate, OS is not impacted yet🧐
2
18
47
8
9K
DrIacovelli's profile picture. Associate Profesor of Medical Oncology at Catholic University, Comprehensive Cancer Center of Rome, Italy. Focused on GU cancers. Husband & father of 2 kids.
Roberto Iacovelli
@DrIacovelli
Feb 13

@neerajaiims reported the final data of #TALAPRO2 comparing Enza + Tala/pbo at #GU25. Clear benefit for OS in overall pts but HRR+ patients have the major role waiting subgroup analysis. A new standard has arrived in clinial practice. @OncoAlert @urofocus @GUOncologyNow @gu_onc

DrIacovelli's tweet image. @neerajaiims reported the final data of #TALAPRO2 comparing Enza + Tala/pbo at #GU25. Clear benefit for OS in overall pts but HRR+ patients have the major role waiting subgroup analysis. A new standard has arrived in clinial practice. @OncoAlert @urofocus @GUOncologyNow @gu_onc
DrIacovelli's tweet image. @neerajaiims reported the final data of #TALAPRO2 comparing Enza + Tala/pbo at #GU25. Clear benefit for OS in overall pts but HRR+ patients have the major role waiting subgroup analysis. A new standard has arrived in clinial practice. @OncoAlert @urofocus @GUOncologyNow @gu_onc
DrIacovelli's tweet image. @neerajaiims reported the final data of #TALAPRO2 comparing Enza + Tala/pbo at #GU25. Clear benefit for OS in overall pts but HRR+ patients have the major role waiting subgroup analysis. A new standard has arrived in clinial practice. @OncoAlert @urofocus @GUOncologyNow @gu_onc
0
9
20
1
893
montypal's profile picture. @cityofhope & @cityofhopeoc prof w focus on #kidneycancer. Want to contribute to my work? E-mail mmayne@coh.org.
Sumanta K. Pal, MD, FASCO
@montypal
Feb 16, 2023

Brilliant delivery of incredibly impressive data from #TALAPRO2 from @neerajaims @huntsmancancer at @ASCO #GU23. What a way to start the meeting - the high-water mark among #PARPi datasets in #mCRPC! See data in both HRR deficient AND non-deficient; a huge win for patients!

montypal's tweet image. Brilliant delivery of incredibly impressive data from #TALAPRO2 from @neerajaims @huntsmancancer at @ASCO #GU23. What a way to start the meeting - the high-water mark among #PARPi datasets in #mCRPC! See data in both HRR deficient AND non-deficient; a huge win for patients!
montypal's tweet image. Brilliant delivery of incredibly impressive data from #TALAPRO2 from @neerajaims @huntsmancancer at @ASCO #GU23. What a way to start the meeting - the high-water mark among #PARPi datasets in #mCRPC! See data in both HRR deficient AND non-deficient; a huge win for patients!
montypal's tweet image. Brilliant delivery of incredibly impressive data from #TALAPRO2 from @neerajaims @huntsmancancer at @ASCO #GU23. What a way to start the meeting - the high-water mark among #PARPi datasets in #mCRPC! See data in both HRR deficient AND non-deficient; a huge win for patients!
montypal's tweet image. Brilliant delivery of incredibly impressive data from #TALAPRO2 from @neerajaims @huntsmancancer at @ASCO #GU23. What a way to start the meeting - the high-water mark among #PARPi datasets in #mCRPC! See data in both HRR deficient AND non-deficient; a huge win for patients!
2
63
180
8
24K
montypal's profile picture. @cityofhope & @cityofhopeoc prof w focus on #kidneycancer. Want to contribute to my work? E-mail mmayne@coh.org.
Sumanta K. Pal, MD, FASCO
@montypal
Jan 14, 2023

Can’t wait till @ASCO #GU23! Mtg starts with a 💥 with long-awaited #TALAPRO2 from @neerajaiims @huntsmancancer. Kudos to him & @AlanBryce9 @MayoCancerCare (#TRITON3); looking fwd to discussion from @Ecastromarcos, who I’ve seen give outstanding talks on #DDR in #prostatecancer.

montypal's tweet image. Can’t wait till @ASCO #GU23! Mtg starts with a 💥 with long-awaited #TALAPRO2 from @neerajaiims @huntsmancancer. Kudos to him & @AlanBryce9 @MayoCancerCare (#TRITON3); looking fwd to discussion from @Ecastromarcos, who I’ve seen give outstanding talks on #DDR in #prostatecancer.
2
22
88
3
17K
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
Oct 13

Overall survival results from the #TALAPRO2 trial in #mCRPC patients. @neerajaiims @huntsmancancer joins Oliver Sartor, MD @EJHospital to discuss the OS results from the TALAPRO-2 trial, which led to approval of talazoparib + enzalutamide for metastatic castration-resistant…

1
3
11
4
1K
Dr_RaviMadan's profile picture. Clinical researcher focused on #ProstateCancer, early recurrence (#BCR) & #immunotherapy. Views are my own & do not represent the National Cancer Institute
Ravi A Madan M.D.
 @Dr_RaviMadan
Feb 13

These are the 2 key slides from the #Talapro2 presentation @asco #GU25 Where HR crosses 1.0 in pts w/no known HRR mutation status & Gd3 toxicity difference of 75% vs 45% I think there is still much to discussion to be had of value of #PARP +#ARPI in unselected #ProstateCancer

Dr_RaviMadan's tweet image. These are the 2 key slides from the #Talapro2 presentation @asco #GU25 Where HR crosses 1.0 in pts w/no known HRR mutation status & Gd3 toxicity difference of 75% vs 45% I think there is still much to discussion to be had of value of #PARP +#ARPI in unselected #ProstateCancer
Dr_RaviMadan's tweet image. These are the 2 key slides from the #Talapro2 presentation @asco #GU25 Where HR crosses 1.0 in pts w/no known HRR mutation status & Gd3 toxicity difference of 75% vs 45% I think there is still much to discussion to be had of value of #PARP +#ARPI in unselected #ProstateCancer
2
23
47
9
7K
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
Oct 17

Talazoparib-enzalutamide combination and quality of life in #mCRPC patients. Nobuaki Matsubara, MD joins @neerajaiims @huntsmancancer to discuss final patient-reported outcomes data from the #TALAPRO2 trial. #WatchNow on UroToday > bit.ly/45C6ld1

urotoday's tweet image. Talazoparib-enzalutamide combination and quality of life in #mCRPC patients. Nobuaki Matsubara, MD joins @neerajaiims @huntsmancancer to discuss final patient-reported outcomes data from the #TALAPRO2 trial. #WatchNow on UroToday > bit.ly/45C6ld1
1
2
2
1
533
OncBrothers's profile picture. Practice changing discussions by community oncologists-Rohit Gosain @RoswellPark & Rahul Gosain @WilmotCancer. OwnViews/NoMedAdvice.COI https://t.co/cJOjp0RvQE
Oncology Brothers
@OncBrothers
Jun 20, 2023

#Talazoparib + Enza now @FDAOncology approved 1L, mCRPC HRR deficient #TALAPRO2: - Improved rPFS in all comers (HR 0.45) - rPFS was higher in BRCA 1/2 - OS immature, but 📈 towards survival Congratulations @neerajaiims et Al. #gusm @OncoAlert #OncTwitter #MedTwitter #brca

OncBrothers's tweet image. #Talazoparib + Enza now @FDAOncology approved 1L, mCRPC HRR deficient #TALAPRO2: - Improved rPFS in all comers (HR 0.45) - rPFS was higher in BRCA 1/2 - OS immature, but 📈 towards survival Congratulations @neerajaiims et Al. #gusm @OncoAlert #OncTwitter #MedTwitter #brca
OncBrothers's tweet image. #Talazoparib + Enza now @FDAOncology approved 1L, mCRPC HRR deficient #TALAPRO2: - Improved rPFS in all comers (HR 0.45) - rPFS was higher in BRCA 1/2 - OS immature, but 📈 towards survival Congratulations @neerajaiims et Al. #gusm @OncoAlert #OncTwitter #MedTwitter #brca
OncBrothers's tweet image. #Talazoparib + Enza now @FDAOncology approved 1L, mCRPC HRR deficient #TALAPRO2: - Improved rPFS in all comers (HR 0.45) - rPFS was higher in BRCA 1/2 - OS immature, but 📈 towards survival Congratulations @neerajaiims et Al. #gusm @OncoAlert #OncTwitter #MedTwitter #brca
OncBrothers's tweet image. #Talazoparib + Enza now @FDAOncology approved 1L, mCRPC HRR deficient #TALAPRO2: - Improved rPFS in all comers (HR 0.45) - rPFS was higher in BRCA 1/2 - OS immature, but 📈 towards survival Congratulations @neerajaiims et Al. #gusm @OncoAlert #OncTwitter #MedTwitter #brca
3
44
115
12
17K
zapatalaguadomd's profile picture. Medical oncologist and internal medicine physician at @INCancerologia interest in #GUcancer and neurooncology Father of luffy 🐶🏴‍☠️and Ricardo 👶
Martin ZapataLaguado
 @zapatalaguadomd
Feb 16, 2023

Very promising data!. Well tolerated. Anemia principal AE Interesting data in PE, and important better QOL. #TALAPRO2 #GU23 @neerajaiims

zapatalaguadomd's tweet image. Very promising data!. Well tolerated. Anemia principal AE Interesting data in PE, and important better QOL. #TALAPRO2 #GU23 @neerajaiims
0
0
9
1
516
ASCO's profile picture. Account of the American Society of Clinical Oncology & its affiliate the Association for Clinical Oncology. Assoc tweets labeled #ASCOAdvocacy. RTs ≠ endorse.
ASCO
 @ASCO
Feb 16, 2023

🎤 Reporting from #GU23: Dr. @neerajaiims & ASCO Expert Dr. @montypal discuss the results of the #TALAPRO2 study and what it means for patients with #mCRPC. #pcsm #prostatecancer

3
28
91
2
16K
montypal's profile picture. @cityofhope & @cityofhopeoc prof w focus on #kidneycancer. Want to contribute to my work? E-mail mmayne@coh.org.
Sumanta K. Pal, MD, FASCO
@montypal
Jan 14, 2023

Terrific 10m overview of #prostatecancer tx landscape by @neerajaiims @huntsmancancer at #DSUIontheBeach23 led by @dipenjparekh. Appreciate his perspective on doublets/triplets & the NEXT study we should be doing in this setting. Eager to see him present #TALAPRO2 at @ASCO #GU23!

montypal's tweet image. Terrific 10m overview of #prostatecancer tx landscape by @neerajaiims @huntsmancancer at #DSUIontheBeach23 led by @dipenjparekh. Appreciate his perspective on doublets/triplets & the NEXT study we should be doing in this setting. Eager to see him present #TALAPRO2 at @ASCO #GU23!
montypal's tweet image. Terrific 10m overview of #prostatecancer tx landscape by @neerajaiims @huntsmancancer at #DSUIontheBeach23 led by @dipenjparekh. Appreciate his perspective on doublets/triplets & the NEXT study we should be doing in this setting. Eager to see him present #TALAPRO2 at @ASCO #GU23!
montypal's tweet image. Terrific 10m overview of #prostatecancer tx landscape by @neerajaiims @huntsmancancer at #DSUIontheBeach23 led by @dipenjparekh. Appreciate his perspective on doublets/triplets & the NEXT study we should be doing in this setting. Eager to see him present #TALAPRO2 at @ASCO #GU23!
montypal's tweet image. Terrific 10m overview of #prostatecancer tx landscape by @neerajaiims @huntsmancancer at #DSUIontheBeach23 led by @dipenjparekh. Appreciate his perspective on doublets/triplets & the NEXT study we should be doing in this setting. Eager to see him present #TALAPRO2 at @ASCO #GU23!
1
18
57
0
7K
montypal's profile picture. @cityofhope & @cityofhopeoc prof w focus on #kidneycancer. Want to contribute to my work? E-mail mmayne@coh.org.
Sumanta K. Pal, MD, FASCO
@montypal
Jun 4, 2023

Incredibly proud of @neerajaiims for publishing #TALAPRO2 in @TheLancet. It’s work deserving of publication in this IF>200 journal - biomarker work is rigorous & outcome + in ITT & biomarker based subgroups. This study is in a lineage of key trials Neeraj has led starting w @SWOG…

montypal's tweet image. Incredibly proud of @neerajaiims for publishing #TALAPRO2 in @TheLancet. It’s work deserving of publication in this IF>200 journal - biomarker work is rigorous & outcome + in ITT & biomarker based subgroups. This study is in a lineage of key trials Neeraj has led starting w @SWOG…
neerajaiims's profile picture. Medical Oncologist. Editor-in-chief: @ASCO Daily News; Presidential Endowed Chair, @HuntsmanCancer (NCI-CCC) @UUtah, FCOI https://t.co/ywWAdZmBWt
Neeraj Agarwal, MD, FASCO
@neerajaiims
Jun 4, 2023

We report in @TheLancet : Primary efficacy data from TALAPRO-2 Phase 3 trial in mCRPC #prostatecancer : Talazoparib + Enza improves outcomes in all subgroups vs Enza. Prospective tissue testing in 100% pts, randomization stratified by HRR status @oncoalert @urotoday @PCF_Science

neerajaiims's tweet image. We report in @TheLancet : Primary efficacy data from TALAPRO-2 Phase 3 trial in mCRPC #prostatecancer : Talazoparib + Enza improves outcomes in all subgroups vs Enza. Prospective tissue testing in 100% pts, randomization stratified by HRR status @oncoalert @urotoday @PCF_Science
neerajaiims's tweet image. We report in @TheLancet : Primary efficacy data from TALAPRO-2 Phase 3 trial in mCRPC #prostatecancer : Talazoparib + Enza improves outcomes in all subgroups vs Enza. Prospective tissue testing in 100% pts, randomization stratified by HRR status @oncoalert @urotoday @PCF_Science
neerajaiims's tweet image. We report in @TheLancet : Primary efficacy data from TALAPRO-2 Phase 3 trial in mCRPC #prostatecancer : Talazoparib + Enza improves outcomes in all subgroups vs Enza. Prospective tissue testing in 100% pts, randomization stratified by HRR status @oncoalert @urotoday @PCF_Science
neerajaiims's tweet image. We report in @TheLancet : Primary efficacy data from TALAPRO-2 Phase 3 trial in mCRPC #prostatecancer : Talazoparib + Enza improves outcomes in all subgroups vs Enza. Prospective tissue testing in 100% pts, randomization stratified by HRR status @oncoalert @urotoday @PCF_Science
17
119
301
26
187K
7
29
109
3
36K
Dr_RaviMadan's profile picture. Clinical researcher focused on #ProstateCancer, early recurrence (#BCR) & #immunotherapy. Views are my own & do not represent the National Cancer Institute
Ravi A Madan M.D.
 @Dr_RaviMadan
Jun 4, 2023

Slide from @vanderweelemd during his excellent #asco23 discussion regarding subsequent #parp inhibitor in #TALAPRO2 @AdamSharpMedOnc @quimmateo @EAntonarakis

Dr_RaviMadan's tweet image. Slide from @vanderweelemd during his excellent #asco23 discussion regarding subsequent #parp inhibitor in #TALAPRO2 @AdamSharpMedOnc @quimmateo @EAntonarakis
1
2
10
1
1K
crisbergerot's profile picture. #PsyOnc | Former Postdoc Fellow & Research Consultant @cityofhope | @IPOSPsychoOncol BOD 2021-2025 | FCOI: https://t.co/EOsx8e8h91
Cristiane D Bergerot, PhD, FASCO
 @crisbergerot
Feb 14

@PauloBergerot & I snapped a selfie with the stellar @neerajaiims after his terrific #GU25 talk on #TALAPRO2! Also great to catch up with @OncHahn and reminisce about the great times we had as fellows!

crisbergerot's tweet image. @PauloBergerot & I snapped a selfie with the stellar @neerajaiims after his terrific #GU25 talk on #TALAPRO2! Also great to catch up with @OncHahn and reminisce about the great times we had as fellows!
0
5
15
0
664
DrKarineTawagi's profile picture. 🇨🇦 | GU Oncologist | Heme/Onc PD @ UIC | Interested in GU, Immuno Onc & Med Ed | @TwoOncDocs podcast
Karine Tawagi MD
 @DrKarineTawagi
Apr 23

GU abstracts for #ASCO25! Schedule & looking forward to: 🔵PARPI in mCSPC #AMPLITUDE -HRRm analysis #TALAPRO2 -prognosis of PSA>0.2 at 6-12mo in mCSPC 🟠analysis of responders in #EV302 -novel nectin-4 ADC -ctDNA in #NIAGARA -abema in MIBC 🟣 #PDIGREE -gut checkpoint in mRCC

DrKarineTawagi's tweet image. GU abstracts for #ASCO25! Schedule & looking forward to: 🔵PARPI in mCSPC #AMPLITUDE -HRRm analysis #TALAPRO2 -prognosis of PSA>0.2 at 6-12mo in mCSPC 🟠analysis of responders in #EV302 -novel nectin-4 ADC -ctDNA in #NIAGARA -abema in MIBC 🟣 #PDIGREE -gut checkpoint in mRCC
DrKarineTawagi's tweet image. GU abstracts for #ASCO25! Schedule & looking forward to: 🔵PARPI in mCSPC #AMPLITUDE -HRRm analysis #TALAPRO2 -prognosis of PSA>0.2 at 6-12mo in mCSPC 🟠analysis of responders in #EV302 -novel nectin-4 ADC -ctDNA in #NIAGARA -abema in MIBC 🟣 #PDIGREE -gut checkpoint in mRCC
DrKarineTawagi's tweet image. GU abstracts for #ASCO25! Schedule & looking forward to: 🔵PARPI in mCSPC #AMPLITUDE -HRRm analysis #TALAPRO2 -prognosis of PSA>0.2 at 6-12mo in mCSPC 🟠analysis of responders in #EV302 -novel nectin-4 ADC -ctDNA in #NIAGARA -abema in MIBC 🟣 #PDIGREE -gut checkpoint in mRCC
3
40
87
14
7K
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
Nov 10

Overall survival results from the #TALAPRO2 trial in #mCRPC patients. @neerajaiims @huntsmancancer joins Oliver Sartor, MD @EJHospital to discuss the OS results from the TALAPRO-2 trial, which led to approval of talazoparib + enzalutamide for metastatic castration-resistant…

0
3
5
0
794
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
Oct 20

Time to response with talazoparib + enzalutamide in patients with #mCRPC in #TALAPRO2. Presentation by Joan Carles, MD, PhD @VHIO. #ESMO25 written coverage by @RKSayyid @UAUrology > bit.ly/3WQp2UY @myESMO

urotoday's tweet image. Time to response with talazoparib + enzalutamide in patients with #mCRPC in #TALAPRO2. Presentation by Joan Carles, MD, PhD @VHIO. #ESMO25 written coverage by @RKSayyid @UAUrology > bit.ly/3WQp2UY @myESMO
0
6
6
2
721
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
Oct 17

Talazoparib-enzalutamide combination and quality of life in #mCRPC patients. Nobuaki Matsubara, MD joins @neerajaiims @huntsmancancer to discuss final patient-reported outcomes data from the #TALAPRO2 trial. #WatchNow on UroToday > bit.ly/45C6ld1

urotoday's tweet image. Talazoparib-enzalutamide combination and quality of life in #mCRPC patients. Nobuaki Matsubara, MD joins @neerajaiims @huntsmancancer to discuss final patient-reported outcomes data from the #TALAPRO2 trial. #WatchNow on UroToday > bit.ly/45C6ld1
1
2
2
1
533
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
Oct 13

Overall survival results from the #TALAPRO2 trial in #mCRPC patients. @neerajaiims @huntsmancancer joins Oliver Sartor, MD @EJHospital to discuss the OS results from the TALAPRO-2 trial, which led to approval of talazoparib + enzalutamide for metastatic castration-resistant…

1
3
11
4
1K
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
Sep 23

Talazoparib-enzalutamide combination and quality of life in #mCRPC patients. Nobuaki Matsubara, MD joins @neerajaiims @huntsmancancer to discuss final patient-reported outcomes data from the #TALAPRO2 trial. #WatchNow on UroToday > bit.ly/45C6ld1

urotoday's tweet image. Talazoparib-enzalutamide combination and quality of life in #mCRPC patients. Nobuaki Matsubara, MD joins @neerajaiims @huntsmancancer to discuss final patient-reported outcomes data from the #TALAPRO2 trial. #WatchNow on UroToday > bit.ly/45C6ld1
0
0
4
0
773
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
Sep 17

Overall survival results from the #TALAPRO2 trial in #mCRPC patients. @neerajaiims @huntsmancancer joins Oliver Sartor, MD @EJHospital to discuss the OS results from the TALAPRO-2 trial, which led to approval of talazoparib + enzalutamide for metastatic castration-resistant…

0
2
6
1
1K
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
Aug 27

Talazoparib-enzalutamide combination and quality of life in #mCRPC patients. Nobuaki Matsubara, MD joins @neerajaiims @huntsmancancer to discuss final patient-reported outcomes data from the #TALAPRO2 trial. #WatchNow on UroToday > bit.ly/45C6ld1

urotoday's tweet image. Talazoparib-enzalutamide combination and quality of life in #mCRPC patients. Nobuaki Matsubara, MD joins @neerajaiims @huntsmancancer to discuss final patient-reported outcomes data from the #TALAPRO2 trial. #WatchNow on UroToday > bit.ly/45C6ld1
0
3
6
2
1K
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
Aug 3

Talazoparib and enzalutamide in unselected #mCRPC patients. @neerajaiims @huntsmancancer joins Oliver Sartor, MD @MayoClinic to discuss updated #TALAPRO2 results exploring talazoparib + enzalutamide in metastatic castration-resistant #ProstateCancer. #WatchNow >…

urotoday's tweet image. Talazoparib and enzalutamide in unselected #mCRPC patients. @neerajaiims @huntsmancancer joins Oliver Sartor, MD @MayoClinic to discuss updated #TALAPRO2 results exploring talazoparib + enzalutamide in metastatic castration-resistant #ProstateCancer. #WatchNow >…
2
2
10
3
2K
IntraMedOnco's profile picture. Las últimas novedades en oncología, eventos de la especialidad y avances terapéuticos. Mantenete actualizado con #IntraMedOnco.
IntraMed Oncología
@IntraMedOnco
Jul 25

Cada vez más evidencia de la sinergia entre iPARPs y ARPIs #TALAPRO2 #TALAPRO3 mejorando la SG de los pacientes con CPRC doi.org/10.1016/S0140-… doi.org/10.1016/S0140-…

IntraMedOnco's tweet image. Cada vez más evidencia de la sinergia entre iPARPs y ARPIs #TALAPRO2 #TALAPRO3 mejorando la SG de los pacientes con CPRC doi.org/10.1016/S0140-… doi.org/10.1016/S0140-…
0
0
1
0
51
nataliagandur's profile picture. Leader GU @InstitutoRoffo #GU #RCC #prostate #bladder #testis #GUcsm #clinicaltrials #Immunotherapy #PrecisionMedicine #OncoAlert #OncoReporte Views Mine
Dra. María Natalia Gandur Quiroga
@nataliagandur
Jul 19

🚨 This week on the OncoAlert RoundUp! 🎯 Unmissable updates from July 11–17 🔥 ➡️ #TALAPRO2 in 🔵 #ProstateCancer ➡️ Geriatric 👴 Assessment in Oncology ➡️ Molecular insights in 🟢 #KidneyCancer (non-ccRCC) ➡️ #POSITIVETrial in 🎗 #BreastCancer ➡️ Mutational forces in 🫁…

OncoAlert's profile picture. 🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨
OncoAlert
@OncoAlert
Jul 18

The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week July 11-17, 2025 👉REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅TALAPRO2 in #ProstateCancer ✅Geriatric Assessment 👴 ✅Molecular Landscape of Non Clear Cell Renal Carcinoma…

0
15
35
4
36K
1
8
13
2
3K
montypal's profile picture. @cityofhope & @cityofhopeoc prof w focus on #kidneycancer. Want to contribute to my work? E-mail mmayne@coh.org.
Sumanta K. Pal, MD, FASCO
@montypal
Jul 17

An amazing contribution to the field. Congrats to the #TALAPRO2 team, led by @neerajaiims @huntsmancancer! Two simultaneous publications in @TheLancet to reflect this practice changing dataset!

neerajaiims's profile picture. Medical Oncologist. Editor-in-chief: @ASCO Daily News; Presidential Endowed Chair, @HuntsmanCancer (NCI-CCC) @UUtah, FCOI https://t.co/ywWAdZmBWt
Neeraj Agarwal, MD, FASCO
@neerajaiims
Jul 17

Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 bit.ly/4lXkLtB and bit.ly/4nNIyOh @PCFnews @urotoday @OncoAlert

neerajaiims's tweet image. Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 bit.ly/4lXkLtB and bit.ly/4nNIyOh @PCFnews @urotoday @OncoAlert
neerajaiims's tweet image. Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 bit.ly/4lXkLtB and bit.ly/4nNIyOh @PCFnews @urotoday @OncoAlert
neerajaiims's tweet image. Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 bit.ly/4lXkLtB and bit.ly/4nNIyOh @PCFnews @urotoday @OncoAlert
neerajaiims's tweet image. Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 bit.ly/4lXkLtB and bit.ly/4nNIyOh @PCFnews @urotoday @OncoAlert
18
69
180
29
35K
1
8
25
1
2K
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
Jul 5

Talazoparib and enzalutamide in unselected #mCRPC patients. @neerajaiims @huntsmancancer joins Oliver Sartor, MD @MayoClinic to discuss updated #TALAPRO2 results exploring talazoparib + enzalutamide in metastatic castration-resistant #ProstateCancer. #WatchNow >…

urotoday's tweet image. Talazoparib and enzalutamide in unselected #mCRPC patients. @neerajaiims @huntsmancancer joins Oliver Sartor, MD @MayoClinic to discuss updated #TALAPRO2 results exploring talazoparib + enzalutamide in metastatic castration-resistant #ProstateCancer. #WatchNow >…
1
1
7
0
1K
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
Jun 19

Talazoparib improves survival in HRR-mutated #mCRPC patients in #TALAPRO2 trial. Karim Fizazi, MD @GustaveRoussy sits down with @CaPsurvivorship @DanaFarber to discuss updated OS data from #TALAPRO2: Talazoparib + enzalutamide cuts death risk by 40% (HR 0.6) in mCRPC with HRR…

urotoday's tweet image. Talazoparib improves survival in HRR-mutated #mCRPC patients in #TALAPRO2 trial. Karim Fizazi, MD @GustaveRoussy sits down with @CaPsurvivorship @DanaFarber to discuss updated OS data from #TALAPRO2: Talazoparib + enzalutamide cuts death risk by 40% (HR 0.6) in mCRPC with HRR…
1
3
10
1
971
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
Jun 8

Talazoparib and enzalutamide in unselected #mCRPC patients. @neerajaiims @huntsmancancer joins Oliver Sartor, MD @MayoClinic to discuss updated #TALAPRO2 results exploring talazoparib + enzalutamide in metastatic castration-resistant #ProstateCancer. #WatchNow >…

urotoday's tweet image. Talazoparib and enzalutamide in unselected #mCRPC patients. @neerajaiims @huntsmancancer joins Oliver Sartor, MD @MayoClinic to discuss updated #TALAPRO2 results exploring talazoparib + enzalutamide in metastatic castration-resistant #ProstateCancer. #WatchNow >…
1
3
24
1
1K
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
Jun 2

Exploratory analyses of HRR alterations by gene subgroup and potential associations with efficacy in the HRR-deficient population from #TALAPRO2. Presentation by Stefanie Zschaebitz, MD. #ASCO25 written coverage by @zklaassen_md @GACancerCenter > bit.ly/45yu4uU @ASCO

0
2
4
1
441
nataliagandur's profile picture. Leader GU @InstitutoRoffo #GU #RCC #prostate #bladder #testis #GUcsm #clinicaltrials #Immunotherapy #PrecisionMedicine #OncoAlert #OncoReporte Views Mine
Dra. María Natalia Gandur Quiroga
@nataliagandur
Jun 1

🌟🔬 Exploratory HRRm analyses from #TALAPRO2 – #ASCO25 Presented by Dr. Stefanie Zschaebitz🌟 @OncoAlert @APCCC_Lugano @Silke_Gillessen @AOmlin TALA + ENZA improved outcomes vs ENZA + PBO in mCRPC with HRRm, especially in BRCA/ATM/CDK12: 🧬 BRCA2: ▪️ ORR: 86.4% vs 31.0% ▪️…

nataliagandur's tweet image. 🌟🔬 Exploratory HRRm analyses from #TALAPRO2 – #ASCO25 Presented by Dr. Stefanie Zschaebitz🌟 @OncoAlert @APCCC_Lugano @Silke_Gillessen @AOmlin TALA + ENZA improved outcomes vs ENZA + PBO in mCRPC with HRRm, especially in BRCA/ATM/CDK12: 🧬 BRCA2: ▪️ ORR: 86.4% vs 31.0% ▪️…
nataliagandur's tweet image. 🌟🔬 Exploratory HRRm analyses from #TALAPRO2 – #ASCO25 Presented by Dr. Stefanie Zschaebitz🌟 @OncoAlert @APCCC_Lugano @Silke_Gillessen @AOmlin TALA + ENZA improved outcomes vs ENZA + PBO in mCRPC with HRRm, especially in BRCA/ATM/CDK12: 🧬 BRCA2: ▪️ ORR: 86.4% vs 31.0% ▪️…
nataliagandur's tweet image. 🌟🔬 Exploratory HRRm analyses from #TALAPRO2 – #ASCO25 Presented by Dr. Stefanie Zschaebitz🌟 @OncoAlert @APCCC_Lugano @Silke_Gillessen @AOmlin TALA + ENZA improved outcomes vs ENZA + PBO in mCRPC with HRRm, especially in BRCA/ATM/CDK12: 🧬 BRCA2: ▪️ ORR: 86.4% vs 31.0% ▪️…
nataliagandur's tweet image. 🌟🔬 Exploratory HRRm analyses from #TALAPRO2 – #ASCO25 Presented by Dr. Stefanie Zschaebitz🌟 @OncoAlert @APCCC_Lugano @Silke_Gillessen @AOmlin TALA + ENZA improved outcomes vs ENZA + PBO in mCRPC with HRRm, especially in BRCA/ATM/CDK12: 🧬 BRCA2: ▪️ ORR: 86.4% vs 31.0% ▪️…
0
11
19
8
2K
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
May 9

Talazoparib improves survival in HRR-mutated #mCRPC patients in #TALAPRO2 trial. Karim Fizazi, MD @GustaveRoussy sits down with @CaPsurvivorship @DanaFarber to discuss updated OS data from #TALAPRO2: Talazoparib + enzalutamide cuts death risk by 40% (HR 0.6) in mCRPC with HRR…

urotoday's tweet image. Talazoparib improves survival in HRR-mutated #mCRPC patients in #TALAPRO2 trial. Karim Fizazi, MD @GustaveRoussy sits down with @CaPsurvivorship @DanaFarber to discuss updated OS data from #TALAPRO2: Talazoparib + enzalutamide cuts death risk by 40% (HR 0.6) in mCRPC with HRR…
0
0
5
0
783
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
May 5

Talazoparib and enzalutamide in unselected #mCRPC patients. @neerajaiims @huntsmancancer joins Oliver Sartor, MD @MayoClinic to discuss updated #TALAPRO2 results exploring talazoparib + enzalutamide in metastatic castration-resistant #ProstateCancer. #WatchNow >…

urotoday's tweet image. Talazoparib and enzalutamide in unselected #mCRPC patients. @neerajaiims @huntsmancancer joins Oliver Sartor, MD @MayoClinic to discuss updated #TALAPRO2 results exploring talazoparib + enzalutamide in metastatic castration-resistant #ProstateCancer. #WatchNow >…
0
3
9
0
1K
No results for "#talapro2"
OncBrothers's profile picture. Practice changing discussions by community oncologists-Rohit Gosain @RoswellPark & Rahul Gosain @WilmotCancer. OwnViews/NoMedAdvice.COI https://t.co/cJOjp0RvQE
Oncology Brothers
@OncBrothers
Feb 16

#GU25 highlights #CommunityOnc: 1. Radical ✂️ vs. XRT high risk PCa 2. #TALAPRO2: PARPi in M1 CRPC 3. #EnzaP: ARPi + LuPSMA in M1 CRPC 4. #NIAGARA update: Resectable MIBC 5. #EV302 update: Metastatic #BladderCancer 6. #CM9ER update: 1L mRCC #OncTwitter #gism @ASCO 1/7

OncBrothers's tweet image. #GU25 highlights #CommunityOnc: 1. Radical ✂️ vs. XRT high risk PCa 2. #TALAPRO2: PARPi in M1 CRPC 3. #EnzaP: ARPi + LuPSMA in M1 CRPC 4. #NIAGARA update: Resectable MIBC 5. #EV302 update: Metastatic #BladderCancer 6. #CM9ER update: 1L mRCC #OncTwitter #gism @ASCO 1/7
6
85
221
143
33K
drenriquegrande's profile picture. Medical Oncology Department Director at Quironsalud Madrid. Opinions are my own. https://t.co/DrJu4J331O
Enrique Grande
@drenriquegrande
Feb 16, 2023

Huge congrats to @neerajaiims Wonderful talk and results with direct implications for the clinic. #Talapro2 at @ASCO #GU23 @OncoAlert

drenriquegrande's tweet image. Huge congrats to @neerajaiims Wonderful talk and results with direct implications for the clinic. #Talapro2 at @ASCO #GU23 @OncoAlert
drenriquegrande's tweet image. Huge congrats to @neerajaiims Wonderful talk and results with direct implications for the clinic. #Talapro2 at @ASCO #GU23 @OncoAlert
1
15
71
2
10K
OncBrothers's profile picture. Practice changing discussions by community oncologists-Rohit Gosain @RoswellPark & Rahul Gosain @WilmotCancer. OwnViews/NoMedAdvice.COI https://t.co/cJOjp0RvQE
Oncology Brothers
@OncBrothers
Jun 20, 2023

#Talazoparib + Enza now @FDAOncology approved 1L, mCRPC HRR deficient #TALAPRO2: - Improved rPFS in all comers (HR 0.45) - rPFS was higher in BRCA 1/2 - OS immature, but 📈 towards survival Congratulations @neerajaiims et Al. #gusm @OncoAlert #OncTwitter #MedTwitter #brca

OncBrothers's tweet image. #Talazoparib + Enza now @FDAOncology approved 1L, mCRPC HRR deficient #TALAPRO2: - Improved rPFS in all comers (HR 0.45) - rPFS was higher in BRCA 1/2 - OS immature, but 📈 towards survival Congratulations @neerajaiims et Al. #gusm @OncoAlert #OncTwitter #MedTwitter #brca
OncBrothers's tweet image. #Talazoparib + Enza now @FDAOncology approved 1L, mCRPC HRR deficient #TALAPRO2: - Improved rPFS in all comers (HR 0.45) - rPFS was higher in BRCA 1/2 - OS immature, but 📈 towards survival Congratulations @neerajaiims et Al. #gusm @OncoAlert #OncTwitter #MedTwitter #brca
OncBrothers's tweet image. #Talazoparib + Enza now @FDAOncology approved 1L, mCRPC HRR deficient #TALAPRO2: - Improved rPFS in all comers (HR 0.45) - rPFS was higher in BRCA 1/2 - OS immature, but 📈 towards survival Congratulations @neerajaiims et Al. #gusm @OncoAlert #OncTwitter #MedTwitter #brca
OncBrothers's tweet image. #Talazoparib + Enza now @FDAOncology approved 1L, mCRPC HRR deficient #TALAPRO2: - Improved rPFS in all comers (HR 0.45) - rPFS was higher in BRCA 1/2 - OS immature, but 📈 towards survival Congratulations @neerajaiims et Al. #gusm @OncoAlert #OncTwitter #MedTwitter #brca
3
44
115
12
17K
TiansterZhang's profile picture. I treat & research GU cancers @UTSW Dallas. Columbia/Harvard Med/Duke alum; Mom & wife Tweets=my opinions ASCO: https://t.co/Whk29PBrMM
Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)
 @TiansterZhang
Jun 3, 2023

@Dr_RaviMadan discussing the quality of life outcomes from #CHAARTED #PROPEL #TALAPRO2 — lots of brainpower on this stage @ASCO #asco23 @OncoAlert

TiansterZhang's tweet image. @Dr_RaviMadan discussing the quality of life outcomes from #CHAARTED #PROPEL #TALAPRO2 — lots of brainpower on this stage @ASCO #asco23 @OncoAlert
TiansterZhang's tweet image. @Dr_RaviMadan discussing the quality of life outcomes from #CHAARTED #PROPEL #TALAPRO2 — lots of brainpower on this stage @ASCO #asco23 @OncoAlert
0
5
10
0
1K
DrIacovelli's profile picture. Associate Profesor of Medical Oncology at Catholic University, Comprehensive Cancer Center of Rome, Italy. Focused on GU cancers. Husband & father of 2 kids.
Roberto Iacovelli
@DrIacovelli
Feb 13

@neerajaiims reported the final data of #TALAPRO2 comparing Enza + Tala/pbo at #GU25. Clear benefit for OS in overall pts but HRR+ patients have the major role waiting subgroup analysis. A new standard has arrived in clinial practice. @OncoAlert @urofocus @GUOncologyNow @gu_onc

DrIacovelli's tweet image. @neerajaiims reported the final data of #TALAPRO2 comparing Enza + Tala/pbo at #GU25. Clear benefit for OS in overall pts but HRR+ patients have the major role waiting subgroup analysis. A new standard has arrived in clinial practice. @OncoAlert @urofocus @GUOncologyNow @gu_onc
DrIacovelli's tweet image. @neerajaiims reported the final data of #TALAPRO2 comparing Enza + Tala/pbo at #GU25. Clear benefit for OS in overall pts but HRR+ patients have the major role waiting subgroup analysis. A new standard has arrived in clinial practice. @OncoAlert @urofocus @GUOncologyNow @gu_onc
DrIacovelli's tweet image. @neerajaiims reported the final data of #TALAPRO2 comparing Enza + Tala/pbo at #GU25. Clear benefit for OS in overall pts but HRR+ patients have the major role waiting subgroup analysis. A new standard has arrived in clinial practice. @OncoAlert @urofocus @GUOncologyNow @gu_onc
0
9
20
1
893
DrMirallas's profile picture. Clinical Fellow @MDAndersonNews |Medical Oncol Drug Develop🫁 23-25 @VHIO | Onc Fellow 18-23 @vallhebron | Vocal 21-25 @COMBarcelona | Profesor 18-25 @SalutUIC
Oriol Mirallas MD
 @DrMirallas
Jun 4, 2023

#ASCO23 #TALAPRO2 Cohort-2: Enzalutamide 160mg +/- Talazoparib 0.5mg QD in HRRm 🗣️ @fizazi_karim ✔️ mPFS NR vs 13.8m HR 0.45 🟰 mOS NR vs 33.7m HR 0.69 p=0.068 ✔️ ORR 67 vs 40% ☠️ AEs 66 vs 37% G3 or higher #ProstateCancer @Movember @ASCO @myESMO @_SEOM @OncoAlert @OncBrothers

DrMirallas's tweet image. #ASCO23 #TALAPRO2 Cohort-2: Enzalutamide 160mg +/- Talazoparib 0.5mg QD in HRRm 🗣️ @fizazi_karim ✔️ mPFS NR vs 13.8m HR 0.45 🟰 mOS NR vs 33.7m HR 0.69 p=0.068 ✔️ ORR 67 vs 40% ☠️ AEs 66 vs 37% G3 or higher #ProstateCancer @Movember @ASCO @myESMO @_SEOM @OncoAlert @OncBrothers
DrMirallas's tweet image. #ASCO23 #TALAPRO2 Cohort-2: Enzalutamide 160mg +/- Talazoparib 0.5mg QD in HRRm 🗣️ @fizazi_karim ✔️ mPFS NR vs 13.8m HR 0.45 🟰 mOS NR vs 33.7m HR 0.69 p=0.068 ✔️ ORR 67 vs 40% ☠️ AEs 66 vs 37% G3 or higher #ProstateCancer @Movember @ASCO @myESMO @_SEOM @OncoAlert @OncBrothers
DrMirallas's tweet image. #ASCO23 #TALAPRO2 Cohort-2: Enzalutamide 160mg +/- Talazoparib 0.5mg QD in HRRm 🗣️ @fizazi_karim ✔️ mPFS NR vs 13.8m HR 0.45 🟰 mOS NR vs 33.7m HR 0.69 p=0.068 ✔️ ORR 67 vs 40% ☠️ AEs 66 vs 37% G3 or higher #ProstateCancer @Movember @ASCO @myESMO @_SEOM @OncoAlert @OncBrothers
DrMirallas's tweet image. #ASCO23 #TALAPRO2 Cohort-2: Enzalutamide 160mg +/- Talazoparib 0.5mg QD in HRRm 🗣️ @fizazi_karim ✔️ mPFS NR vs 13.8m HR 0.45 🟰 mOS NR vs 33.7m HR 0.69 p=0.068 ✔️ ORR 67 vs 40% ☠️ AEs 66 vs 37% G3 or higher #ProstateCancer @Movember @ASCO @myESMO @_SEOM @OncoAlert @OncBrothers
0
5
7
0
3K
Dr_RaviMadan's profile picture. Clinical researcher focused on #ProstateCancer, early recurrence (#BCR) & #immunotherapy. Views are my own & do not represent the National Cancer Institute
Ravi A Madan M.D.
 @Dr_RaviMadan
Feb 16, 2023

#Talapro2 #ProstateCancer @asco #GU23 @neerajaiims @Huntsman_GU presents the data of first line #mCRPC of #parp inhibitor & enzalutamide Clear benefit in progression free survival w/expected added toxicity Surprising that with a nearly 50% event rate, OS is not impacted yet🧐

Dr_RaviMadan's tweet image. #Talapro2 #ProstateCancer @asco #GU23 @neerajaiims @Huntsman_GU presents the data of first line #mCRPC of #parp inhibitor & enzalutamide Clear benefit in progression free survival w/expected added toxicity Surprising that with a nearly 50% event rate, OS is not impacted yet🧐
Dr_RaviMadan's tweet image. #Talapro2 #ProstateCancer @asco #GU23 @neerajaiims @Huntsman_GU presents the data of first line #mCRPC of #parp inhibitor & enzalutamide Clear benefit in progression free survival w/expected added toxicity Surprising that with a nearly 50% event rate, OS is not impacted yet🧐
Dr_RaviMadan's tweet image. #Talapro2 #ProstateCancer @asco #GU23 @neerajaiims @Huntsman_GU presents the data of first line #mCRPC of #parp inhibitor & enzalutamide Clear benefit in progression free survival w/expected added toxicity Surprising that with a nearly 50% event rate, OS is not impacted yet🧐
Dr_RaviMadan's tweet image. #Talapro2 #ProstateCancer @asco #GU23 @neerajaiims @Huntsman_GU presents the data of first line #mCRPC of #parp inhibitor & enzalutamide Clear benefit in progression free survival w/expected added toxicity Surprising that with a nearly 50% event rate, OS is not impacted yet🧐
2
18
47
8
9K
montypal's profile picture. @cityofhope & @cityofhopeoc prof w focus on #kidneycancer. Want to contribute to my work? E-mail mmayne@coh.org.
Sumanta K. Pal, MD, FASCO
@montypal
Feb 16, 2023

Brilliant delivery of incredibly impressive data from #TALAPRO2 from @neerajaims @huntsmancancer at @ASCO #GU23. What a way to start the meeting - the high-water mark among #PARPi datasets in #mCRPC! See data in both HRR deficient AND non-deficient; a huge win for patients!

montypal's tweet image. Brilliant delivery of incredibly impressive data from #TALAPRO2 from @neerajaims @huntsmancancer at @ASCO #GU23. What a way to start the meeting - the high-water mark among #PARPi datasets in #mCRPC! See data in both HRR deficient AND non-deficient; a huge win for patients!
montypal's tweet image. Brilliant delivery of incredibly impressive data from #TALAPRO2 from @neerajaims @huntsmancancer at @ASCO #GU23. What a way to start the meeting - the high-water mark among #PARPi datasets in #mCRPC! See data in both HRR deficient AND non-deficient; a huge win for patients!
montypal's tweet image. Brilliant delivery of incredibly impressive data from #TALAPRO2 from @neerajaims @huntsmancancer at @ASCO #GU23. What a way to start the meeting - the high-water mark among #PARPi datasets in #mCRPC! See data in both HRR deficient AND non-deficient; a huge win for patients!
montypal's tweet image. Brilliant delivery of incredibly impressive data from #TALAPRO2 from @neerajaims @huntsmancancer at @ASCO #GU23. What a way to start the meeting - the high-water mark among #PARPi datasets in #mCRPC! See data in both HRR deficient AND non-deficient; a huge win for patients!
2
63
180
8
24K
TiansterZhang's profile picture. I treat & research GU cancers @UTSW Dallas. Columbia/Harvard Med/Duke alum; Mom & wife Tweets=my opinions ASCO: https://t.co/Whk29PBrMM
Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)
 @TiansterZhang
Feb 16, 2023

Always dynamic, @neerajaiims takes us thru #TALAPRO2 for mCRPC — talazoparib w enzalutamide prolonged disease progression vs enza w placebo. Effect more in HRR+ pts but ➕in all pts. Some cytopenias which we expect on PARP inhibitors. Great work from @PfizerOncMed & study teams!

TiansterZhang's tweet image. Always dynamic, @neerajaiims takes us thru #TALAPRO2 for mCRPC — talazoparib w enzalutamide prolonged disease progression vs enza w placebo. Effect more in HRR+ pts but ➕in all pts. Some cytopenias which we expect on PARP inhibitors. Great work from @PfizerOncMed & study teams!
TiansterZhang's tweet image. Always dynamic, @neerajaiims takes us thru #TALAPRO2 for mCRPC — talazoparib w enzalutamide prolonged disease progression vs enza w placebo. Effect more in HRR+ pts but ➕in all pts. Some cytopenias which we expect on PARP inhibitors. Great work from @PfizerOncMed & study teams!
TiansterZhang's tweet image. Always dynamic, @neerajaiims takes us thru #TALAPRO2 for mCRPC — talazoparib w enzalutamide prolonged disease progression vs enza w placebo. Effect more in HRR+ pts but ➕in all pts. Some cytopenias which we expect on PARP inhibitors. Great work from @PfizerOncMed & study teams!
TiansterZhang's tweet image. Always dynamic, @neerajaiims takes us thru #TALAPRO2 for mCRPC — talazoparib w enzalutamide prolonged disease progression vs enza w placebo. Effect more in HRR+ pts but ➕in all pts. Some cytopenias which we expect on PARP inhibitors. Great work from @PfizerOncMed & study teams!
0
12
36
0
6K
montypal's profile picture. @cityofhope & @cityofhopeoc prof w focus on #kidneycancer. Want to contribute to my work? E-mail mmayne@coh.org.
Sumanta K. Pal, MD, FASCO
@montypal
Jan 14, 2023

Can’t wait till @ASCO #GU23! Mtg starts with a 💥 with long-awaited #TALAPRO2 from @neerajaiims @huntsmancancer. Kudos to him & @AlanBryce9 @MayoCancerCare (#TRITON3); looking fwd to discussion from @Ecastromarcos, who I’ve seen give outstanding talks on #DDR in #prostatecancer.

montypal's tweet image. Can’t wait till @ASCO #GU23! Mtg starts with a 💥 with long-awaited #TALAPRO2 from @neerajaiims @huntsmancancer. Kudos to him & @AlanBryce9 @MayoCancerCare (#TRITON3); looking fwd to discussion from @Ecastromarcos, who I’ve seen give outstanding talks on #DDR in #prostatecancer.
2
22
88
3
17K
Dr_RaviMadan's profile picture. Clinical researcher focused on #ProstateCancer, early recurrence (#BCR) & #immunotherapy. Views are my own & do not represent the National Cancer Institute
Ravi A Madan M.D.
 @Dr_RaviMadan
Jun 4, 2023

Slide from @vanderweelemd during his excellent #asco23 discussion regarding subsequent #parp inhibitor in #TALAPRO2 @AdamSharpMedOnc @quimmateo @EAntonarakis

Dr_RaviMadan's tweet image. Slide from @vanderweelemd during his excellent #asco23 discussion regarding subsequent #parp inhibitor in #TALAPRO2 @AdamSharpMedOnc @quimmateo @EAntonarakis
1
2
10
1
1K
montypal's profile picture. @cityofhope & @cityofhopeoc prof w focus on #kidneycancer. Want to contribute to my work? E-mail mmayne@coh.org.
Sumanta K. Pal, MD, FASCO
@montypal
Jan 14, 2023

Terrific 10m overview of #prostatecancer tx landscape by @neerajaiims @huntsmancancer at #DSUIontheBeach23 led by @dipenjparekh. Appreciate his perspective on doublets/triplets & the NEXT study we should be doing in this setting. Eager to see him present #TALAPRO2 at @ASCO #GU23!

montypal's tweet image. Terrific 10m overview of #prostatecancer tx landscape by @neerajaiims @huntsmancancer at #DSUIontheBeach23 led by @dipenjparekh. Appreciate his perspective on doublets/triplets & the NEXT study we should be doing in this setting. Eager to see him present #TALAPRO2 at @ASCO #GU23!
montypal's tweet image. Terrific 10m overview of #prostatecancer tx landscape by @neerajaiims @huntsmancancer at #DSUIontheBeach23 led by @dipenjparekh. Appreciate his perspective on doublets/triplets & the NEXT study we should be doing in this setting. Eager to see him present #TALAPRO2 at @ASCO #GU23!
montypal's tweet image. Terrific 10m overview of #prostatecancer tx landscape by @neerajaiims @huntsmancancer at #DSUIontheBeach23 led by @dipenjparekh. Appreciate his perspective on doublets/triplets & the NEXT study we should be doing in this setting. Eager to see him present #TALAPRO2 at @ASCO #GU23!
montypal's tweet image. Terrific 10m overview of #prostatecancer tx landscape by @neerajaiims @huntsmancancer at #DSUIontheBeach23 led by @dipenjparekh. Appreciate his perspective on doublets/triplets & the NEXT study we should be doing in this setting. Eager to see him present #TALAPRO2 at @ASCO #GU23!
1
18
57
0
7K
zapatalaguadomd's profile picture. Medical oncologist and internal medicine physician at @INCancerologia interest in #GUcancer and neurooncology Father of luffy 🐶🏴‍☠️and Ricardo 👶
Martin ZapataLaguado
 @zapatalaguadomd
Feb 16, 2023

Very promising data!. Well tolerated. Anemia principal AE Interesting data in PE, and important better QOL. #TALAPRO2 #GU23 @neerajaiims

zapatalaguadomd's tweet image. Very promising data!. Well tolerated. Anemia principal AE Interesting data in PE, and important better QOL. #TALAPRO2 #GU23 @neerajaiims
0
0
9
1
516
TiansterZhang's profile picture. I treat & research GU cancers @UTSW Dallas. Columbia/Harvard Med/Duke alum; Mom & wife Tweets=my opinions ASCO: https://t.co/Whk29PBrMM
Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)
 @TiansterZhang
Oct 13, 2023

Clear cut discussion from @DrYukselUrun on biomarker selection for PARP inhibitors! Covers #PROPEL, #TALAPRO2, & #MAGNITUDE trials and recent genomic selections/HRR selections for combo selection. @SIU_urology #SIU2023Istanbul

TiansterZhang's tweet image. Clear cut discussion from @DrYukselUrun on biomarker selection for PARP inhibitors! Covers #PROPEL, #TALAPRO2, & #MAGNITUDE trials and recent genomic selections/HRR selections for combo selection. @SIU_urology #SIU2023Istanbul
TiansterZhang's tweet image. Clear cut discussion from @DrYukselUrun on biomarker selection for PARP inhibitors! Covers #PROPEL, #TALAPRO2, & #MAGNITUDE trials and recent genomic selections/HRR selections for combo selection. @SIU_urology #SIU2023Istanbul
TiansterZhang's tweet image. Clear cut discussion from @DrYukselUrun on biomarker selection for PARP inhibitors! Covers #PROPEL, #TALAPRO2, & #MAGNITUDE trials and recent genomic selections/HRR selections for combo selection. @SIU_urology #SIU2023Istanbul
TiansterZhang's tweet image. Clear cut discussion from @DrYukselUrun on biomarker selection for PARP inhibitors! Covers #PROPEL, #TALAPRO2, & #MAGNITUDE trials and recent genomic selections/HRR selections for combo selection. @SIU_urology #SIU2023Istanbul
0
7
18
0
3K
montypal's profile picture. @cityofhope & @cityofhopeoc prof w focus on #kidneycancer. Want to contribute to my work? E-mail mmayne@coh.org.
Sumanta K. Pal, MD, FASCO
@montypal
Jan 30

Great overview of the #TALAPRO2 study by @mar_nataliya @ChaoCompCancer at an @OncLiveSOSS hosted by @TDorffOnc @cityofhope - can’t want to see @neerajaiims @huntsmancancer update the data at @ASCO #GU25!

montypal's tweet image. Great overview of the #TALAPRO2 study by @mar_nataliya @ChaoCompCancer at an @OncLiveSOSS hosted by @TDorffOnc @cityofhope - can’t want to see @neerajaiims @huntsmancancer update the data at @ASCO #GU25!
montypal's tweet image. Great overview of the #TALAPRO2 study by @mar_nataliya @ChaoCompCancer at an @OncLiveSOSS hosted by @TDorffOnc @cityofhope - can’t want to see @neerajaiims @huntsmancancer update the data at @ASCO #GU25!
montypal's tweet image. Great overview of the #TALAPRO2 study by @mar_nataliya @ChaoCompCancer at an @OncLiveSOSS hosted by @TDorffOnc @cityofhope - can’t want to see @neerajaiims @huntsmancancer update the data at @ASCO #GU25!
1
8
25
2
3K
montypal's profile picture. @cityofhope & @cityofhopeoc prof w focus on #kidneycancer. Want to contribute to my work? E-mail mmayne@coh.org.
Sumanta K. Pal, MD, FASCO
@montypal
Feb 16, 2023

In <1h, @ASCO #GU23 kicks off w @neerajaiims @huntsmancancer & @AlanBryce9 @MayoCancerCare delivering results of #TALAPRO2 & #TRITON3, respectively. Looking fwd to a terrific discussion from @Ecastromarcos. What a way to kick things off! Kudos to planning cmte on a great agenda!

montypal's tweet image. In &amp;lt;1h, @ASCO #GU23 kicks off w @neerajaiims @huntsmancancer &amp;amp; @AlanBryce9 @MayoCancerCare delivering results of #TALAPRO2 &amp;amp; #TRITON3, respectively. Looking fwd to a terrific discussion from @Ecastromarcos. What a way to kick things off! Kudos to planning cmte on a great agenda!
0
10
42
3
7K
urotoday's profile picture. Largest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
UroToday.com
@urotoday
Oct 17

Talazoparib-enzalutamide combination and quality of life in #mCRPC patients. Nobuaki Matsubara, MD joins @neerajaiims @huntsmancancer to discuss final patient-reported outcomes data from the #TALAPRO2 trial. #WatchNow on UroToday > bit.ly/45C6ld1

urotoday's tweet image. Talazoparib-enzalutamide combination and quality of life in #mCRPC patients. Nobuaki Matsubara, MD joins @neerajaiims @huntsmancancer to discuss final patient-reported outcomes data from the #TALAPRO2 trial. #WatchNow on UroToday &amp;gt; bit.ly/45C6ld1
1
2
2
1
533
OncBrothers's profile picture. Practice changing discussions by community oncologists-Rohit Gosain @RoswellPark & Rahul Gosain @WilmotCancer. OwnViews/NoMedAdvice.COI https://t.co/cJOjp0RvQE
Oncology Brothers
@OncBrothers
Feb 16, 2023

1. #TALAPRO2:  Talazoparib + Enza vs Enza alone, 1L mCRPC, all comers - HRR def had ⬆ benefit (HR 0.48) - HRR non-def/unknown or prev ARi also had good response - Improved PFS (HR 0.63) in all comers - 1 MDS, 1 AML, & 10 PEs as part of AEs 👏🏽 👏🏽@neerajaiims et Al.

OncBrothers's tweet image. 1. #TALAPRO2:  Talazoparib + Enza vs Enza alone, 1L mCRPC, all comers - HRR def had ⬆ benefit (HR 0.48) - HRR non-def/unknown or prev ARi also had good response - Improved PFS (HR 0.63) in all comers - 1 MDS, 1 AML, &amp;amp; 10 PEs as part of AEs 👏🏽 👏🏽@neerajaiims et Al.
OncBrothers's tweet image. 1. #TALAPRO2:  Talazoparib + Enza vs Enza alone, 1L mCRPC, all comers - HRR def had ⬆ benefit (HR 0.48) - HRR non-def/unknown or prev ARi also had good response - Improved PFS (HR 0.63) in all comers - 1 MDS, 1 AML, &amp;amp; 10 PEs as part of AEs 👏🏽 👏🏽@neerajaiims et Al.
OncBrothers's tweet image. 1. #TALAPRO2:  Talazoparib + Enza vs Enza alone, 1L mCRPC, all comers - HRR def had ⬆ benefit (HR 0.48) - HRR non-def/unknown or prev ARi also had good response - Improved PFS (HR 0.63) in all comers - 1 MDS, 1 AML, &amp;amp; 10 PEs as part of AEs 👏🏽 👏🏽@neerajaiims et Al.
OncBrothers's tweet image. 1. #TALAPRO2:  Talazoparib + Enza vs Enza alone, 1L mCRPC, all comers - HRR def had ⬆ benefit (HR 0.48) - HRR non-def/unknown or prev ARi also had good response - Improved PFS (HR 0.63) in all comers - 1 MDS, 1 AML, &amp;amp; 10 PEs as part of AEs 👏🏽 👏🏽@neerajaiims et Al.
1
0
7
0
2K

Something went wrong.


Something went wrong.


United States Trends